CN112933068A - Metabolite of lactic acid bacteria and use thereof for preparing blood vessel health care composition - Google Patents
Metabolite of lactic acid bacteria and use thereof for preparing blood vessel health care composition Download PDFInfo
- Publication number
- CN112933068A CN112933068A CN202011463972.6A CN202011463972A CN112933068A CN 112933068 A CN112933068 A CN 112933068A CN 202011463972 A CN202011463972 A CN 202011463972A CN 112933068 A CN112933068 A CN 112933068A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- hydroxy
- metabolite
- acid
- tci028
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 241000894006 Bacteria Species 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title claims description 37
- 239000002207 metabolite Substances 0.000 title claims description 21
- 230000003840 blood vessel health Effects 0.000 title description 2
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims abstract description 28
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims abstract description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 90
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 65
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 65
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 65
- 230000014509 gene expression Effects 0.000 claims description 45
- 101150023483 MSR1 gene Proteins 0.000 claims description 26
- 230000036996 cardiovascular health Effects 0.000 claims description 26
- 239000012228 culture supernatant Substances 0.000 claims description 19
- FSNCEEGOMTYXKY-UHFFFAOYSA-N 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid Chemical compound N1C2=CC=CC=C2C2=C1CNC(C(=O)O)C2 FSNCEEGOMTYXKY-UHFFFAOYSA-N 0.000 claims description 17
- YRQLKHIYTFTZSB-MRVPVSSYSA-N 1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid Natural products OC(=O)[C@@H]1CNCc2[nH]c3ccccc3c12 YRQLKHIYTFTZSB-MRVPVSSYSA-N 0.000 claims description 17
- 101150067145 SCARB1 gene Proteins 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 239000004310 lactic acid Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 229940088623 biologically active substance Drugs 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 abstract description 16
- 230000000975 bioactive effect Effects 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 15
- 239000006143 cell culture medium Substances 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 7
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- GUAHPAJOXVYFON-ZETCQYMHSA-N (8S)-8-amino-7-oxononanoic acid zwitterion Chemical compound C[C@H](N)C(=O)CCCCCC(O)=O GUAHPAJOXVYFON-ZETCQYMHSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 240000002234 Allium sativum Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108020001027 Ribosomal DNA Proteins 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 235000004611 garlic Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 230000006438 vascular health Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- MCUYKWWMATYNBK-UHFFFAOYSA-N C1NC(CC=2C3=CC=CC=C3NC12)C(=O)O.C1NC(CC=2C3=CC=CC=C3NC12)C(=O)O Chemical compound C1NC(CC=2C3=CC=CC=C3NC12)C(=O)O.C1NC(CC=2C3=CC=CC=C3NC12)C(=O)O MCUYKWWMATYNBK-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- RLHGDSNHSMOQHZ-UHFFFAOYSA-N OC(C(=O)O)C(C)C.OC(C(=O)O)C(C)C Chemical compound OC(C(=O)O)C(C)C.OC(C(=O)O)C(C)C RLHGDSNHSMOQHZ-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000012156 elution solvent Substances 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
- WAPPRYMYMNVAFR-UHFFFAOYSA-N 2-sulfanylethanol Chemical compound OCCS.OCCS WAPPRYMYMNVAFR-UHFFFAOYSA-N 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- SVNYOZUGSHKOJR-UHFFFAOYSA-N CC(C)CC(O)C(O)=O.CC(C)CC(O)C(O)=O Chemical compound CC(C)CC(O)C(O)=O.CC(C)CC(O)C(O)=O SVNYOZUGSHKOJR-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091005487 SCARB1 Proteins 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000009849 vacuum degassing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a metabolite of lactic acid bacteria, comprising at least one bioactive substance selected from the group consisting of: 2-hydroxy-4-methylvaleric acid and 2-hydroxy-3-methylbutanoic acid.
Description
Technical Field
The invention relates to a metabolite of lactic acid bacteria, in particular to the metabolite of lactic acid bacteria and application of the metabolite of lactic acid bacteria in preparing a blood vessel health-care composition.
Background
Blood vessels are used to circulate around the body, and blood can carry oxygen, nutrients and various chemical substances to various organs, which is an important transportation network. However, as the age increases, the vessels gradually lose elasticity, and the structure of the vessels begins to change, with large vessel diseases such as dilated deformation and small vessel diseases causing obstruction.
The main cause of common cardiovascular diseases is vascular occlusion, which progresses from the normal blood vessels, congestional coronary sclerosis possibly caused by fat accumulation or other reasons, to blood vessel stenosis and finally to blood vessel occlusion. If the arteries congenitally harden in the coronary arteries, the coronary arteries are blocked, coronary heart disease can be caused, and the normal functions of the heart are affected. If the artery is congestively hardened in the blood vessel of the brain, the brain cell is damaged, even the cerebral vessel is broken, and even if the cerebral vessel is healed, the cerebral vessel often has remarkable sequelae. In addition, vascular embolism caused by atherosclerosis may damage valves and cause valvular heart disease.
In conclusion, there is a significant need for the development of cardiovascular health care compositions based on the improvement of modern life levels and the improvement of health care concepts.
Disclosure of Invention
Accordingly, in one embodiment, a metabolite of a lactic acid bacterium comprises at least one biologically active substance selected from the group consisting of: 2-hydroxy-4-methylvaleric acid (2-hydroxy-4-methylpentanoid acid) and 2-hydroxy-3-methylbutanoic acid (2-hydroxy-3-methylbutanoic acid).
In some embodiments, the lactic acid bacterium is Lactobacillus plantarum (TCI 028), and Lactobacillus plantarum TCI028 has accession number DSM 33108.
In some embodiments, the metabolites of lactic acid bacteria further comprise: 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid (1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid).
In one embodiment, the use of a metabolite of a lactic acid bacterium for the preparation of a cardiovascular health composition, wherein the lactic acid bacterium is lactobacillus plantarum TCI028, deposited under DSM 33108.
In some embodiments, the metabolite of lactobacillus plantarum TCI028 comprises at least one biologically active substance selected from the group consisting of: 1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid, 2-hydroxy-4-methylpentanoic acid and 2-hydroxy-3-methylbutyric acid.
In some embodiments, the metabolite of lactobacillus plantarum TCI028 is prepared by a method comprising the steps of: culturing Lactobacillus plantarum TCI028 in a culture medium to obtain a culture of Lactobacillus plantarum TCI028, then centrifuging the culture of Lactobacillus plantarum TCI028 and collecting the supernatant to obtain a metabolite of lactic acid bacteria.
In some embodiments, the foregoing cardiovascular health compositions are used to inhibit MSR1 gene expression.
In some embodiments, the foregoing cardiovascular health compositions are used to increase SCARB1 gene expression.
In one embodiment, the use of a 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid for the preparation of a cardiovascular healthcare composition.
In some embodiments, the foregoing vascular health compositions are used to inhibit MSR1 gene expression.
In some embodiments, the foregoing vascular health compositions are used to increase SCARB1 gene expression.
In some embodiments, the aforementioned 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid is isolated and purified from a methanol layer extract of a culture supernatant of lactobacillus plantarum TCI028, and lactobacillus plantarum TCI028 has accession number DSM 33108.
In one embodiment, the use of 2-hydroxy-4-methylpentanoic acid in the preparation of a cardiovascular health care composition. In some embodiments, the foregoing cardiovascular health compositions are used to inhibit MSR1 gene expression.
In some examples, the aforementioned 2-hydroxy-4-methylvaleric acid is isolated and purified from methanol layer extract of culture supernatant of Lactobacillus plantarum TCI028, and Lactobacillus plantarum TCI028 has accession number DSM 33108.
In one embodiment, the use of 2-hydroxy-3-methylbutyric acid for the preparation of a cardiovascular health composition. In some embodiments, the foregoing cardiovascular health compositions are used to inhibit MSR1 gene expression.
In some examples, the 2-hydroxy-3-methylbutyric acid is isolated and purified from a methanol layer extract of a culture supernatant of Lactobacillus plantarum TCI028, and Lactobacillus plantarum TCI028 has been deposited under the accession number DSM 33108.
In summary, according to any of the embodiments, 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid, 2-hydroxy-4-methylpentanoic acid, 2-hydroxy-3-methylbutyric acid, or a combination thereof, inhibits MSR1 gene expression, thereby providing cardiovascular health. In some embodiments, the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid, 2-hydroxy-4-methylpentanoic acid or 2-hydroxy-3-methylbutyric acid is derived from lactobacillus plantarum TCI028, accession No. DSM 33108. In some embodiments, the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid also increases SCARB1 gene expression, thereby providing cardiovascular health.
The invention is described in detail below with reference to the drawings and specific examples, but the invention is not limited thereto.
Drawings
FIG. 1 is the hydrogen nuclear magnetic resonance spectrum of compound TCI-028-002.
FIG. 2 is the hydrogen nuclear magnetic resonance spectrum of compound TCI-028-003-.
FIG. 3 is an electrospray ionization mass spectrum of compound TCI-028-002.
FIG. 4 is an electrospray ionization mass spectrum of compound TCI-028-003.
FIG. 5 is the hydrogen nuclear magnetic resonance spectrum of the compound TCI-028-001.
FIG. 6 is an electrospray ionization mass spectrum of compound TCI-028-001.
FIG. 7 is a data chart showing the expression amount of MSR1 gene.
FIG. 8 is a data chart showing the expression amount of SCARB1 gene.
Preservation of biological materials
Lactobacillus plantarum TCI028(Lactobacillus plantarum TCI028), deposited at 2.5.2019 in the German Collection of microorganisms DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen), address: branrey City of Germany, Hoffing street 7B, deposited under the number DSM 33108.
Detailed Description
In one embodiment, at least one of the following compounds can be used to prepare a cardiovascular healthcare composition: 2-hydroxy-4-methylpentanoic acid (2-hydroxy-4-methylpentanoic acid), 2-hydroxy-3-methylbutyric acid (2-hydroxy-3-methylbutanoic acid), and 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid (1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid).
Wherein, the structural formula of each compound is shown in the following table I:
watch 1
In other words, a subject is provided with at least one compound as described above or a cardiovascular healthcare composition prepared therefrom, which is useful for cardiovascular healthcare of the subject. Accordingly, the aforementioned compounds may also be referred to as biologically active substances. Wherein, the receptor can be human.
In some embodiments, at least one of the foregoing compounds or a cardiovascular health composition prepared therefrom inhibits MSR1 gene expression, thereby providing cardiovascular health.
In some embodiments, the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid or cardiovascular healthcare compositions prepared therewith also increase SCARB1 gene expression, thereby providing cardiovascular healthcare.
In some embodiments, the bioactive substances may be artificially synthesized or derived from Lactobacillus plantarum (Lactobacillus plantarum).
In some embodiments, the various bioactive substances described above are metabolites of Lactobacillus plantarum.
In some embodiments, the lactobacillus plantarum can be lactobacillus plantarum TCI 028. Among them, Lactobacillus plantarum TCI028(Lactobacillus plantarum TCI028) was deposited with the German Collection of microorganisms under the accession number DSM 33108.
In some embodiments, Lactobacillus plantarum (TCI 028) is a strain isolated from garlic.
Lactobacillus plantarum TCI028 is a gram-positive anaerobic bacterium with a surface colony diameter of about 3mm, round, smooth, fine, white, and occasionally light or dark yellow in color. The lactobacillus plantarum TCI028 has a growth temperature of 15 to 45 ℃ and survives in an environment of pH 5 to 7.
In other words, metabolites of Lactobacillus plantarum TCI028 can be used for the preparation of a cardiovascular health composition.
In some embodiments, the metabolite of lactobacillus plantarum TCI028 is prepared by a method comprising the steps of: culturing Lactobacillus plantarum TCI028 in a culture medium to obtain a culture of Lactobacillus plantarum TCI028, then centrifuging the culture of Lactobacillus plantarum TCI028 and collecting the supernatant (also called culture supernatant) to obtain the metabolite of lactic acid bacteria. In other words, the metabolite of lactobacillus plantarum TCI028 includes a substance metabolized and secreted by lactobacillus plantarum TCI028 into a culture solution.
In some embodiments, the "metabolite" may include a substance secreted into the culture medium by the lactobacillus plantarum TCI028 when the lactobacillus plantarum TCI028 is cultured, but does not include the lactobacillus plantarum TCI028 entity.
In some embodiments, the metabolite of the plant lactic acid bacterium comprises at least one biologically active substance selected from the group consisting of: 2-hydroxy-4-methylvaleric acid and 2-hydroxy-3-methylbutanoic acid.
In some embodiments, 2-hydroxy-4-methylpentanoic acid is isolated and purified from methanol layer extract of culture supernatant of Lactobacillus plantarum TCI 028.
In some embodiments, 2-hydroxy-4-methylpentanoic acid is isolated and purified from 40% methanol layer extract of culture supernatant of Lactobacillus plantarum TCI 028.
In some examples, 2-hydroxy-4-methylvaleric acid is obtained by column chromatography of culture supernatant of Lactobacillus plantarum TCI028 with 40% aqueous methanol as a eluting solvent, followed by flash column chromatography with 20% aqueous methanol as an eluting solvent.
In some embodiments, 2-hydroxy-4-methylpentanoic acid can be used to inhibit MSR1 gene expression.
In some embodiments, 2-hydroxy-3-methylbutyric acid is isolated and purified from methanol layer extract of culture supernatant of Lactobacillus plantarum TCI 028.
In some embodiments, 2-hydroxy-3-methylbutyric acid is isolated and purified from 40% methanol layer extract of the culture supernatant of Lactobacillus plantarum TCI 028.
In some examples, 2-hydroxy-3-methylbutyric acid is obtained by performing column chromatography on a culture supernatant of Lactobacillus plantarum TCI028 with 40% aqueous methanol as a eluting solvent to obtain a 40% methanol layer extract, and performing flash column chromatography with 20% aqueous methanol as an eluting solvent.
In some embodiments, 2-hydroxy-4-methylbutyric acid can be used to inhibit MSR1 gene expression.
In some embodiments, the metabolites of the plant lactic acid bacteria may further comprise: 1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid.
In some embodiments, the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid is isolated and purified from methanol layer extract of culture supernatant of lactobacillus plantarum TCI 028.
In some embodiments, the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid is isolated and purified from 40% methanol layer extract of culture supernatant of lactobacillus plantarum TCI 028.
In some examples, the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid is obtained by performing column chromatography on a culture supernatant of Lactobacillus plantarum TCI028 with 40% methanol aqueous solution as a eluting solvent to obtain a 40% methanol layer extract, and performing flash column chromatography with 80% methanol aqueous solution as an eluting solvent.
In some embodiments, 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid can be used to inhibit MSR1 gene expression.
In some embodiments, 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid can be used to increase SCARB1 gene expression.
In some embodiments, the foregoing cardiovascular health compositions are used to inhibit MSR1 gene expression.
In some embodiments, the foregoing cardiovascular health compositions are used to increase SCARB1 gene expression.
In some embodiments, the cardiovascular health composition may be a pharmaceutical. In other words, the medicament comprises an effective content of the at least one bioactive substance.
In some embodiments, the cardiovascular healthcare composition described previously may be an edible composition. In other words, the edible composition comprises an effective amount of the at least one bioactive substance. In some embodiments, the edible composition may be formulated into a food product or may be a food additive (food additive), i.e., added during the preparation of the food material by prior art methods to produce a food product, or added during the production of a food product. Herein, the food product may be a product formulated with edible material for ingestion by humans or animals.
In some embodiments, the food product may be, but is not limited to: beverages (leafages), fermented foods (fermented foods), bakery products (bakery products), health foods (health foods) and dietary supplements (dietary supplements).
The first example is as follows: strain screening and identification
Grinding Bulbus Allii, mashing to obtain Bulbus Allii juice, or adding sterilized water into Bulbus Allii, and homogenizing to obtain Bulbus Allii homogenized solution. Placing garlic juice or garlic homogenate in solid medium (BD Difco)TMLactobacillus MRS Broth, DF0881-17-5) Upper platePlates were incubated at 28 ℃ until single colonies formed. A plurality of single colonies are picked and the single colonies are used for strain identification. The 16S ribosomal gene (16SrDNA) sequence (SEQ ID NO:1) of the isolated strain was obtained by Polymerase Chain Reaction (PCR). Then, the sequence of SEQ ID NO:1 was aligned with the 16S ribosomal gene (16SrDNA) of other Lactobacillus plantarum subspecies using the National Center for Biotechnology Information (NCBI) website, and the similarity between the 16S ribosomal gene sequence of these single colonies and other Lactobacillus plantarum subspecies is shown in Table two. As can be seen, these single colonies showed similarity of more than 95.85 with other Lactobacillus plantarum strains, and thus they were named Lactobacillus plantarum TCI 028. The strain name and the strain identification result are shown in the following table II:
in addition, Lactobacillus plantarum TCI028 was deposited with the German Collection of microorganisms under the deposit number DSM 33108.
Example two: preparation of metabolites
1. Lactobacillus plantarum (Lactobacillus plantarum) TCI028 was inoculated in a culture Medium (MRS) in a inoculum size of 1% (v/v) and cultured at 37 ℃ for 18 hours to obtain a inoculum solution. After the cell suspension was centrifuged at 5000rpm for 20 minutes, the culture supernatant was collected. This culture supernatant was taken as a sample of TCI028 for subsequent analysis.
2. A2L sample of TCI028 was injected with Diaion HP-20 packing material (pore size)
Particle size 0.5mm, available from Mitsubishi Chemical Co., Japan) filled
Analytical column (5 μm, C18(2),
70x7mm from Phenomenex, USA), and in order of gradientThe TCI028 sample was subjected to Column Chromatography (Column Chromatography) with 100% water, 20% aqueous methanol, 40% aqueous methanol, 60% aqueous methanol, 100% methanol as a wash solvent to isolate five fractions. The five tiers are referred to as tier 1, tier 2, tier 3, tier 4, and tier 5, respectively.
The weights of solids obtained after removal of the eluting solvents in layers 1 to 5 were 20.9 g (i.e., solids from layer 1), 6.3 g (i.e., solids from layer 2), 4.3 g (i.e., solids from layer 3), 2.9 g (i.e., solids from layer 4), and 2.7 g (i.e., solids from layer 5), respectively.
3. The Layer 3 obtained by elution with 40% aqueous methanol was subjected to flash column Chromatography using a chromatographic strip (TLC aluminum sheets, RP-18F254-S,0.25mm, Merck, Germany) and an elution solvent having a gradient of 20% aqueous methanol, 40% aqueous methanol, 60% aqueous methanol, 80% aqueous methanol and 100% methanol in this order, i.e., Thin-Layer Chromatography (Thin-Layer Chromatography), to separate 5 sublayers (hereinafter referred to as sublayer 1, sublayer 2, sublayer 3, sublayer 4 and sublayer 5, respectively).
4. Subjecting the sub-layer 1 to reverse-phase chromatography (RPC) by using a methanol-water elution solvent with a volume ratio of 1:9 to purify to obtain two compounds TCI-028-002 and TCI-028-003. Wherein, the reverse-phase chromatography is to use Diaion HP-20 packing material (aperture)
Particle size 0.5mm, available from Mitsubishi Chemical Co., Japan) injection filled
Analytical column (5 μm, C18(2),
250X 10mm, available from Phenomenex, USA).
The chemical structures of the compounds TCI-028-002 and TCI-028-003 were analyzed by hydrogen nuclear magnetic resonance spectroscopy and electrospray ionization mass spectrometry. Thus, the hydrogen nuclear magnetic resonance spectra of the compounds TCI-028-002 and TCI-028-03 are shown in FIGS. 1 to 2, and the electrospray ionization mass spectra of the compounds TCI-028-002 and TCI-028-03 are shown in FIGS. 3 to 4. And determining the chemical structure and chemical name of each compound according to the obtained hydrogen nuclear magnetic resonance spectrum and electrospray ionization mass spectrum, as shown in the table III below.
Watch III
The 1D and 2D spectra of the NMR spectrometer were obtained using an Ascend 400MHz, Bruker Co. Inc. (Germany), and chemical shifts (chemical shift) were expressed in δ in ppm. The electrospray ionization mass spectrometer is a tandem mass spectrum-two-dimensional ion trap tandem Fourier transform mass spectrum and ESI-MS/MS: measured using a Bruker amaZon SL system in m/z.
5. The sub-layer 4 is subjected to reverse-phase chromatography by using a methanol-water eluting solvent with the volume ratio of 4:6 to purify to obtain the compound TCI-028-001. Wherein, the reverse-phase chromatography is to use Diaion HP-20 packing material (aperture)
Particle size 0.5mm, available from Mitsubishi Chemical Co., Japan) injection filled
Analytical column (5 μm, C18(2),
250X 10mm, available from Phenomenex, USA.
The chemical structure of the compound TCI-028-001 is analyzed by hydrogen nuclear magnetic resonance spectroscopy and electrospray ionization mass spectrometry. Here, the hydrogen nuclear magnetic resonance spectrum of the compound TCI-028-001 is shown in FIG. 5, and the electrospray ionization mass spectrum of the compound TCI-028-001 is shown in FIG. 6. And, the chemical structure and chemical name of the compound TCI-028-001 are determined according to the obtained hydrogen nuclear magnetic resonance spectrum and electrospray ionization mass spectrum, as shown in the following table four.
Watch four
Among them, reverse phase Chromatography was performed by using an Agilent 1200 column High Performance Liquid Chromatography (HPLC). In an Agilent 1200 series high performance liquid chromatography, the degassing device is an Agilent vacuum degassing device 1322A; the conveying of the leaching solvent is Agilent quaternary pump G1311A; the variable Wavelength Detector is (MWD) Agilent G1314B; the photodiode Array Detector (DAD) is Agilent 1260Infinity DAD VL G1315D, and its detection wavelength is 210nm, 280nm, 320nm and 365nm (Agilent Germany).
Wherein the flash column chromatography is realized by using a pressure liquid chromatography (MPLC) (model number)
Rf +, from Teledyne ISCO) with a filler material Merck
RP-18 (pore size 40-63um, model Art.0250).
Example three: atherosclerosis-associated gene detection
1. Human monocytic cell line (THP-1 cell) purchased from American type culture Collection ATCC (model: TIB-202) at 1.5X 10 per well5In this manner, the cells were seeded in 6-well culture plates containing 2mL of cell culture medium per well.
Here, the cell culture medium is RPMI 1640 medium (Gibco RPMI medium 1640; Thermo Fisher Scientific) supplemented with 10% Fetal Bovine Serum (FBS), 0.05mM 2-mercaptoethanol (2-mercaptoethanol), 100 units/mL penicillin (penicillin) and 1ug/1mL streptomycin.
2. Exchange 500nM phorbol-12-tetradecanoyl-13-acetate (phorbol 12-myrisitate 13-acetate, PMA) into cell culture medium and 5% CO at 37 deg.C2For 48 hours to stimulate the differentiation of THP-1 cells into macrophages.
3. Fresh cell culture medium was changed and monitored at 37 ℃ with 5% CO2The culture was continued for 48 hours.
4. The cell culture medium in each well of the culture tray was removed.
5. The differentiated cells were divided into 5 groups, i.e., experimental group 1, experimental group 2, experimental group 3, control group and control group, and the following experimental media were added to each group:
experimental group 1: 2mL of cell culture medium containing 20g/mL of compound TCI-028 001 and 100ng/mL of Lipopolysaccharides (LPS) was added to each well.
Experimental group 2: 2mL of cell culture medium containing 20g/mL of compound TCI-028-002 and 100ng/mL of lipopolysaccharide was added to each well.
Experimental group 3: 2mL of cell culture medium containing 20g/mL of compound TCI-028-003 and 100ng/mL of lipopolysaccharide was added to each well.
Control group: 2mL of cell culture medium containing 100ng/mL lipopolysaccharide was added to each well.
Control group: 2mL of cell culture medium was added per well (i.e. no additional compound and lipopolysaccharide was added).
6. After culturing each group for 48 hours, the cells of each group were disrupted with cell lysate to form cell solutions, respectively.
7. RNA in the cell solutions of each group was extracted using an RNA extraction reagent kit (purchased from Geneaid, Taiwan, Lot No. FC24015-G). Then, 2000 nanograms (ng) of the extracted RNA were used as templates in each group
III reverse transcriptase (from Invitrogene, USA) reverse transcription by primer bindingThe application is as follows. Then, the reverse-transcribed products were subjected to quantitative Real-Time reverse transcription polymerase chain reaction (quantitative Real-Time reverse transcription polymerase chain reaction) using ABI StepOnePlus TM Real-Time PCR system (Thermo Fisher Scientific Co., U.S.A.) and KAPA SYBR FAST (2X) (available from KAPA Biosystems, U.S.A.) with the combined primers of MSR1 genes shown in Table five, respectively, to observe the expression amounts of MSR1 gene of each group of cells. Further, three groups of reverse transcription products of the control group, the control group and the experimental group 1 were subjected to quantitative Real-Time reverse transcription polymerase chain reaction using ABI StepOnePlusTM Real-Time PCR system and KAPA SYBR FAST (2X) (purchased from KAPA Biosystems, USA) with the combination primers of SCARB1 genes shown in Table 3, respectively, to observe the expression amount of SCARB1 gene in each group of cells. Here, the quantitative real-time RT-PCR instrument was set to react at 95 ℃ for 1 second and at 60 ℃ for 20 seconds for a total of 40 loops, and 2 cycles of reaction were used-ΔCtThe method is used for gene quantification. In this case, the quantitative real-time reverse transcription polymerase chain reaction using cDNA can indirectly quantify the mRNA expression level of each gene, and the expression level of the protein encoded by each gene can be estimated.
Watch five
It should be noted that the expression quantities of the genes shown in the figures mentioned below are expressed in relative ratios, wherein the standard deviation is calculated by using the STDEV formula of Excel software, and analyzed by the single Student t-test (Student t-test) to determine whether there is a statistically significant difference. In the drawings, the term "indicates a p value of less than 0.05, the term" indicates a p value of less than 0.01, and the term "indicates a p value of less than 0.001. As more "x", the more significant the statistical difference.
Refer to fig. 7. The expression level of the MSR1 gene in the control group was regarded as 1 (i.e., 100%) and the expression level of the MSR1 gene in the experimental group 1 was 0.66 (i.e., 66%) relative to the control group. The expression amount of the MSR1 gene was 0.91 (i.e., 91%) in experimental group 2 relative to the control group. The expression amount of the MSR1 gene was 0.92 (i.e., 92%) in experimental group 3 relative to the control group. The expression level of the MSR1 gene was 1.47 (i.e., 147%) relative to the control group.
Comparing the control group with the control group, it was found that the expression level of MSR1 gene was increased when the cells were induced by lipopolysaccharide. Further comparing each experimental group with the control group or control group, the expression level of MSR1 gene was reduced in the cells treated with compounds TCI-028-001, TCI-028-002 and TCI-028-003, and even lower than that in the case of induction without lipopolysaccharide. Wherein, the MSR1 gene expression of the cells is reduced most after the TCI-028-001 compound treatment. As can be seen, the compounds TCI-028-001, TCI-028-002 and TCI-028-003 can reduce the expression of the MSR1 gene related to the atherosclerosis, wherein the effect of the compound TCI-028-001 is the best.
Refer to fig. 8. The expression level of the SCARB1 gene in the control group was regarded as 1 (i.e., 100%) and the expression level of the SCARB1 gene in the experimental group 1 was 1.72 (i.e., 172%) relative to the control group. The expression level of the SCARB1 gene was 0.78 (i.e., 78%) relative to the control group.
Comparing the control group with the control group, it was found that when cells were induced by lipopolysaccharide, the expression level of SCARB1 gene was decreased. Further comparing the test group 1 with the control group or control group, it can be seen that the expression level of SCARB1 gene in the cells after the treatment with TCI-028-001 was increased and even higher than that in the induction without lipopolysaccharide.
Therefore, the metabolite of lactobacillus plantarum TCI028 can inhibit the expression level of MSR1 gene of immune cells and improve the expression level of SCARB1 gene of immune cells, thereby avoiding atherosclerosis cardiovascular disease.
Although the present invention has been described with reference to the preferred embodiments, it should be understood that various changes and modifications can be made without departing from the spirit and scope of the invention as defined by the appended claims.
[ sequence listing ]
<110> Dajiang biomedical corporation Ltd
<120> metabolites of lactic acid bacteria and their use for the preparation of vascular health compositions
<150> 62/946,471
<151> 2019-12-11
<160> 7
<170> PatentIn version 3.5
<210> 1
<211> 1224
<212> DNA
<213> Lactobacillus plantarum
<400> 1
gggacggggg ggggtgctat acatgcaagt cgaacgaact ctggtattga ttggtgcttg 60
catcatgatt tacatttgag tgagtggcga actggtgagt aacacgtggg aaacctgccc 120
agaagcggga taacacctgg aaacagatgc taataccgca taacaacttg gaccgcatgg 180
tccgagcttg aaagatggct tcggctatca cttttggatg gtcccgcggc gtattagcta 240
gatggtgggg taagctcacc atggcaatga tacgtagccg acctgagagg gtaatcggcc 300
acattgggac tgagacacgg cccaaactcc tacgggaggc agcagtaggg aatcttccac 360
aatggacgaa agtctgatga gaacgccgcg tgagtgaaga agggtttcgg ctcgtaaaac 420
tctgttgtta aagaagaaca tatctgagag taactgttca ggtattgacg gtatttaacc 480
agaaagccac ggctaactac gtgccgcacc gcggtaatac gtaggtggca agcgttgtcc 540
ggatttattg ggcgtaaagc gagcgcaggc ggttttttaa gtctgatgtg aaagccttcg 600
gctcaaccga agaagtgcat cggaaactgg gaactgagtg cagaagagga cagtggaact 660
ccatgtgtag cggtgaaatg cgtagatata tggaagaaca ccagtggcga aggcggctgt 720
ctggtctgta actgacgctg aggctcgaaa gtatgggagc aacaggatta gataccctgg 780
tagtccatac cgtaaacgat gaatgctaag tgttggaggg tttccgccct tcagtgctgc 840
agctaacgca ttaagcattc cgcctggggg agtacggccg caagctgaac tcaaaggaat 900
ttgacggggg cccgcacaag cggtggagca tggtggttta attcgaagct acgcgagacc 960
ttaccagtct tgacatacta tgcaatctag agattagacg ttcccttcgg gacatgatac 1020
agtgctgcat gtgtcgtcag ctcgtgtcgt gagatgtggt agtcccgcac gagcgcaccc 1080
tataatcagt gcagcaatag tggcaactct ggtgagactg cgtgactacc gagagtggga 1140
tgattcatca tcatgcctta gactgactac acgtgctaac atggatgtac acgaggttgc 1200
gaactctcgc ggaagagata ggct 1224
<210> 2
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesis of primers
<400> 2
acatgggaat gcaatagatg aaatc 25
<210> 3
<211> 26
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesis of primers
<400> 3
gcacttgttc ttctttcata gccata 26
<210> 4
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesis of primers
<400> 4
actccgactc tgggctcttc a 21
<210> 5
<211> 18
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesis of primers
<400> 5
ggcctccggg ctgtagaa 18
<210> 6
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesis of primers
<400> 6
catgtacgtt gctatccagg c 21
<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Synthesis of primers
<400> 7
ctccttaatg tcacgcacga t 21
Claims (18)
1. A metabolite of a lactic acid bacterium comprising at least one biologically active substance selected from the group consisting of: 2-hydroxy-4-methylvaleric acid and 2-hydroxy-3-methylbutanoic acid.
2. The metabolite according to claim 1, wherein the lactic acid bacterium is Lactobacillus plantarum TCI028, deposited under DSM 33108.
3. The metabolite of lactic acid bacteria according to claim 1, further comprising: 1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid.
4. Use of a metabolite of a lactic acid bacterium for the preparation of a cardiovascular health composition, wherein the lactic acid bacterium is Lactobacillus plantarum TCI028, deposited under DSM 33108.
5. The use according to claim 4, wherein the metabolite of Lactobacillus plantarum TCI028 comprises at least one biologically active substance selected from the group consisting of: 1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid, 2-hydroxy-4-methylpentanoic acid and 2-hydroxy-3-methylbutyric acid.
6. The use according to claim 4, wherein the metabolite of Lactobacillus plantarum TCI028 is produced by a method comprising: culturing the Lactobacillus plantarum TCI028 in a culture medium to obtain a culture of the Lactobacillus plantarum TCI028, then centrifuging the culture of the Lactobacillus plantarum TCI028 and collecting a culture supernatant to obtain the metabolite of the lactic acid bacteria.
7. The use of claim 4, wherein the cardiovascular health composition is for inhibiting MSR1 gene expression.
8. The use of claim 4, wherein the cardiovascular health composition is for increasing SCARB1 gene expression.
9. Use of 1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid in preparing a cardiovascular health composition.
10. The use of claim 9, wherein the cardiovascular health composition is for inhibiting MSR1 gene expression.
11. The use of claim 9, wherein the cardiovascular health composition is for increasing SCARB1 gene expression.
12. The use according to claim 9, wherein the 1,2,3,4-tetrahydro- β -carboline-3-carboxylic acid is isolated and purified from methanol layer extract of culture supernatant of lactobacillus plantarum TCI028, deposited under DSM 33108.
13. Use of 2-hydroxy-4-methylvaleric acid for preparing a cardiovascular health composition.
14. The use of claim 13, wherein the cardiovascular health composition is for inhibiting MSR1 gene expression.
15. The use according to claim 13, wherein the 2-hydroxy-4-methylpentanoic acid is isolated and purified from methanol layer extract of culture supernatant of Lactobacillus plantarum TCI028, deposited under DSM 33108.
16. Use of 2-hydroxy-3-methylbutyric acid for the preparation of a cardiovascular health composition.
17. The use of claim 16, wherein the cardiovascular health composition is for inhibiting MSR1 gene expression.
18. The use according to claim 16, wherein the 2-hydroxy-3-methylbutyric acid is isolated and purified from the methanol layer extract of the culture supernatant of lactobacillus plantarum TCI028, deposited under DSM 33108.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946471P | 2019-12-11 | 2019-12-11 | |
| US62/946,471 | 2019-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112933068A true CN112933068A (en) | 2021-06-11 |
Family
ID=76234830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011463972.6A Withdrawn CN112933068A (en) | 2019-12-11 | 2020-12-11 | Metabolite of lactic acid bacteria and use thereof for preparing blood vessel health care composition |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112933068A (en) |
| TW (1) | TW202122075A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1496400A (en) * | 2001-01-19 | 2004-05-12 | 巴斯福股份公司 | Methods and microorganisms for the production of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (HMBPA) |
| WO2015052086A1 (en) * | 2013-10-09 | 2015-04-16 | Nestec S.A. | Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome |
| TW201927318A (en) * | 2017-12-21 | 2019-07-16 | 大江生醫股份有限公司 | Lactobacillus plantarum for cholesterol digestion and a composition containing the same |
| US20190224259A1 (en) * | 2018-01-19 | 2019-07-25 | Tci Co., Ltd. | Fermentation product of punica granatum and uses thereof |
-
2020
- 2020-12-11 CN CN202011463972.6A patent/CN112933068A/en not_active Withdrawn
- 2020-12-11 TW TW109143981A patent/TW202122075A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1496400A (en) * | 2001-01-19 | 2004-05-12 | 巴斯福股份公司 | Methods and microorganisms for the production of 3-(2-hydroxy-3-methyl-butyrylamino)-propionic acid (HMBPA) |
| WO2015052086A1 (en) * | 2013-10-09 | 2015-04-16 | Nestec S.A. | Compositions comprising citrulline and leucine and their use in the treatment of diabetes and metabolic syndrome |
| TW201927318A (en) * | 2017-12-21 | 2019-07-16 | 大江生醫股份有限公司 | Lactobacillus plantarum for cholesterol digestion and a composition containing the same |
| US20190224259A1 (en) * | 2018-01-19 | 2019-07-25 | Tci Co., Ltd. | Fermentation product of punica granatum and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| ASIFA QURESHI ET AL.: "BACTERIA ASSOCIATED WITH NON-ALCOHOLIC FERMENTED BAMBOO SHOOT FOOD PRODUCT" * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202122075A (en) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Antioxidant and immune-enhancing effects of probiotic Lactobacillus plantarum 200655 isolated from kimchi | |
| Bourrie et al. | Traditional kefir reduces weight gain and improves plasma and liver lipid profiles more successfully than a commercial equivalent in a mouse model of obesity | |
| US9387228B2 (en) | Agent for prevention or amelioration of obesity | |
| Martinez-Villaluenga et al. | Multifunctional properties of soy milk fermented by Enterococcus faecium strains isolated from raw soy milk | |
| KR101494279B1 (en) | Lactobacillus plantarum KY1032 having inhibitory activity against adipocyte-specific gene expression and adipocyte differentiation, and product containing thereof as an effective factor | |
| KR102033031B1 (en) | Lactobacillus plantarum tci378 and its uses in losing fat and improving gastrointestinal functions | |
| Park et al. | Lactobacillus plantarum LG42 isolated from gajami sik‐hae inhibits adipogenesis in 3T3‐L1 adipocyte | |
| Fuloria et al. | Synbiotic effects of fermented rice on human health and wellness: a natural beverage that boosts immunity | |
| CN113286872B (en) | DYSO SMOBACTER as new bacterial genus of gastrointestinal microbiota and its use | |
| Sadeghi et al. | Food applications of probiotic yeasts; focusing on their techno-functional, postbiotic and protective capabilities | |
| WO2019208150A1 (en) | Composition for inhibiting fat accumulation | |
| Wang et al. | Effect of Lactobacillus acidophilus KLDS 1.0738 on miRNA expression in in vitro and in vivo models of β-lactoglobulin allergy | |
| Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
| Gaudioso et al. | Microbial and metabolic characterization of organic artisanal sauerkraut fermentation and study of gut health-promoting properties of sauerkraut brine | |
| AU2022356019A1 (en) | Novel probiotics and use thereof | |
| Zhao et al. | Bifidobacterium longum subsp. longum K5 alleviates inflammatory response and prevents intestinal barrier injury induced by LPS in vitro based on comparative genomics | |
| KR101426276B1 (en) | The products containing probiotic Lactobacillus plantarum HY7712 having activity preventing from the atherogenic legion formation and foam cell formation, which caused heart disease and stroke as effective component | |
| EP2958578B1 (en) | Functional peptides for obesity disorders | |
| CN117106672B (en) | Bifidobacterium breve for improving aging-related cognitive impairment and application thereof | |
| KR101508586B1 (en) | Novel Strains of Enterococcus faecalis MD366 with Anti-Obesity Ability | |
| US20230172221A1 (en) | Method for the production of traditional kefir | |
| Baliyan et al. | Probiotics from the bovine raw milk of Lahaul valley showed cis-9, trans-11 conjugated linoleic acid isomer and antioxidant activity with food formulation ability | |
| CN112933068A (en) | Metabolite of lactic acid bacteria and use thereof for preparing blood vessel health care composition | |
| Oh et al. | Comparison of Cell‐Free Extracts from Three Newly Identified Lactobacillus plantarum Strains on the Inhibitory Effect of Adipogenic Differentiation and Insulin Resistance in 3T3‐L1 Adipocytes | |
| CN115992059B (en) | Lactobacillus johnsonii for producing feruloyl esterase and application thereof in relieving ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210611 |